,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2017-07-11 06:42:00,"Arena Pharmaceuticals (ARNA) jumped nearly 50% on Tuesday morning, after it said that an experimental drug that targets a rare but deadly lung disease met its primary goal in a Phase II study.",0.9247029423713684,0.02824506349861622,0.047052040696144104,positive,0.896457850933075
1,2017-07-11 06:42:00,"Arena said that ralinepag, its treatment for pulmonary arterial hypertension, improved pulmonary vascular resistance (PVR) compared to a placebo in a 61-person study.",0.9383264183998108,0.03087311051785946,0.030800428241491318,positive,0.9074532985687256
2,2017-07-11 06:42:00,"Leerink's Joseph Schwartz and Dae Gon Ha were encouraged by the results, reiterating an Outperform rating on the stock and raising their price target to $53:

Today's topline data builds upon strong favorable, albeitin vitro, data which effectively re-positions Arena as a biotechnology company driven by proprietary pipeline rather than the long-standing image of a weight-loss drug company.",0.8849284052848816,0.01682627759873867,0.0982453003525734,positive,0.8681021332740784
3,2017-07-11 06:42:00,"On the heels of today's ralinepag data, we believe investors will begin to assign greater value to the company's proprietary pipeline - etrasimod and APD371 - that could present further upside in not only mass-mkt.",0.9356151223182678,0.014452100731432438,0.04993274062871933,positive,0.921163022518158
4,2017-07-11 06:42:00,"indications like ulcerative colitis (UC) and pain, but also in the rare manifestations including pyoderma gangrenosum (PG) and extraintestinal manifestations (EIM).",0.03631305694580078,0.2399708777666092,0.723716139793396,neutral,-0.2036578208208084
5,2017-07-11 06:42:00,"As it pertains to ralinepag in PAH, we are raising our probability of success (PoS) to 50% (from 30% previously), which raises our PT to $53/shr.",0.9550620317459106,0.01759336329996586,0.027344534173607826,positive,0.9374686479568481
6,2017-07-11 06:42:00,Arena shares are up 49.5% to $27.50 in recent trading; the iShares NASDAQ Biotechnology Index (IBB) is up 0.5%.,0.9421783685684204,0.021315671503543854,0.03650592640042305,positive,0.9208626747131348
7,2017-07-11 06:42:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
